Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible s...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelmaseih, Ramy, Abdelmasih, Randa, Hasan, Mustajab, Hamza, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260193/
https://www.ncbi.nlm.nih.gov/pubmed/34262805
http://dx.doi.org/10.7759/cureus.15467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260193/
https://www.ncbi.nlm.nih.gov/pubmed/34262805
http://dx.doi.org/10.7759/cureus.15467

Ejemplares similares